Post-marketing quality assessment of some brands of rosuvastatin tablets available in Jos, North-Central Nigeria
- PMID: 40287767
- PMCID: PMC12034138
- DOI: 10.1186/s13065-025-01470-w
Post-marketing quality assessment of some brands of rosuvastatin tablets available in Jos, North-Central Nigeria
Abstract
Rosuvastatin is a synthetic statin medication approved for the management of lipid disorders and also for preventing cardiovascular disease in at-risk individuals. Generic rosuvastatin formulations have been developed which are comparatively lower in cost and also assumed to be bio-similar to the innovator brand Crestor®. The present study investigated the chemical and physical attributes together with the in vitro bioequivalence profiles of four generic brands of rosuvastatin calcium tablets marketed in Jos, Nigeria in comparison to the reference brand. The tablet dimensions (thickness and diameter), weight variation, friability, hardness, disintegration time and dissolution profiles were evaluated in accordance to standard procedures. The samples were also assayed using Ultraviolet-Visible spectrophotometry at wavelength of 242.5 nm in methanol. In vitro bioequivalence was evaluated by determining the difference ( ) and similarity ( ) factors. The generic brands all complied with the pharmacopoeial specifications for weight variation, friability and disintegration. In addition, the tablet brands tested all had active drug content ranging from 94.92 to 109.2% and released over 80% of rosuvastatin calcium within the first twenty minutes of the dissolution studies thereby complying with pharmacopoeial requirements for content and dissolution respectively. All brands had similarity factor ( ) values ranging from 50 to 100 and difference factor ( ) values between 0 to 15% at pH 6.6, thus implying that the brands can be used interchangeably with the innovator brand. The chemical and physical tests carried out reveal that the locally marketed brands of rosuvastatin calcium are of good quality and meet the required regulatory standards.
Keywords: Bioequivalence; Dyslipidemia; Nigeria; Quality; Rosuvastatin.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not Applicable. Competing interests: The authors declare no competing interests.
Figures


Similar articles
-
In vitro quality evaluation of leading brands of ciprofloxacin tablets available in Bangladesh.BMC Res Notes. 2017 May 30;10(1):185. doi: 10.1186/s13104-017-2507-y. BMC Res Notes. 2017. PMID: 28558832 Free PMC article.
-
In vitro Comparative Quality Assessment of Different Brands of Furosemide Tablets Marketed in Northwest Ethiopia.Drug Des Devel Ther. 2020 Nov 24;14:5119-5128. doi: 10.2147/DDDT.S280203. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 33262573 Free PMC article.
-
In vitro comparative quality evaluation of different brands of carbamazepine tablets commercially available in Dessie town, Northeast Ethiopia.BMC Pharmacol Toxicol. 2023 May 25;24(1):35. doi: 10.1186/s40360-023-00670-1. BMC Pharmacol Toxicol. 2023. PMID: 37231520 Free PMC article.
-
In vitro bioequivalence study of nine brands of artesunate tablets marketed in Nigeria.J Vector Borne Dis. 2008 Mar;45(1):60-5. J Vector Borne Dis. 2008. PMID: 18399319
-
A critical review of brand and generic alendronate for the treatment of osteoporosis.Springerplus. 2013 Oct 21;2(1):550. doi: 10.1186/2193-1801-2-550. eCollection 2013. Springerplus. 2013. PMID: 25674402 Free PMC article. Review.
References
-
- Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1-45. - PubMed
-
- Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidaemias. Nat Rev Cardiol. 2021;18(10):689–700. 10.1038/s41569-021-00541-4. - PubMed
-
- de Brito Alves JL, Trindade da Costa PC. Probiotic for dyslipidemia prevention and treatment. London: Academic Press; 2022.
LinkOut - more resources
Full Text Sources
Miscellaneous